Newsroom
Sorted by: Latest
-
RÉSULTAT EN REPLI EN 2025 LANCEMENT D’UN PLAN DE RETOUR À NOTRE TRAJECTOIRE DE CROISSANCE RENTABLE
ECULLY, France--(BUSINESS WIRE)--Regulatory News: GROUPE SEB (Paris:SK): Déclaration de Stanislas de Gramont, Directeur Général du Groupe SEB : « Dans un environnement resté complexe, le Groupe SEB enregistre en 2025 une légère croissance organique de ses ventes, mais un repli marqué de sa rentabilité, reflet d’un exercice difficile. La solidité de notre innovation, les bonnes dynamiques en entretien des sols, soin du linge et articles culinaires, ainsi que la croissance soutenue de nos ventes...
-
Result Down in 2025 Launch of a Plan to Return to Our Profitable Growth Trajectory
ECULLY, France--(BUSINESS WIRE)--Regulatory News: GROUPE SEB (Paris:SK): Statement by Stanislas de Gramont, Chief Executive Officer of Groupe SEB: “In an environment that remained complex, Groupe SEB recorded a slight organic sales growth in 2025, but a marked decrease in its profitability, reflecting a difficult year. The strength of our innovation and the good momentum in floor care, linen care and cookware, as well as sustained growth in our online sales, were not enough to offset major cycl...
-
Fruition Earns monday.com Platinum Partner Status in APAC
SYDNEY--(BUSINESS WIRE)--Fruition has officially attained a pinnacle of the monday Partner Program within 2.5 years since its operations began. Headquartered in Sydney, this consultancy has officially become a monday.com Platinum Partner across APAC. Being in the highest tier places Fruition among the elite group of 2,000+ global partners. This recognition is often distinguished by exceptional delivery quality and client satisfaction. The monday Platinum path for service-focused partners requir...
-
Bureau Veritas: Croissance organique leader dans le secteur à 6,5 % en 2025
COURBEVOIE, France--(BUSINESS WIRE)--Bureau Veritas (BOURSE:BVI): Chiffres clés1 2025 › Chiffre d'affaires (CA) de 6 466,4 millions d'euros en 2025, en hausse de 6,5% sur une base organique (dont 6,3 % de croissance organique au quatrième trimestre). A taux de change constant, la croissance s’est établie à 7,3 % en glissement annuel et à 3,6 % sur une base reportée, › Résultat opérationnel ajusté de 1 052,9 millions d'euros, en hausse de 5,7 % par rapport aux 996,2 millions d'euros en 2024, soi...
-
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025
COURBEVOIE, France--(BUSINESS WIRE)--Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency,...
-
DoorDash to Wind Down Deliveroo and Wolt Operations in Four Countries
SAN FRANCISCO & HELSINKI & LONDON--(BUSINESS WIRE)--DoorDash, Inc. (NASDAQ: DASH) today announced it is exiting four countries across its Deliveroo and Wolt brands: Qatar, Singapore, Japan, and Uzbekistan. The company will begin an orderly wind-down process in each country and will work closely with local teams and partners to support employees, merchants, consumers, riders, and couriers through the transition. These decisions follow a multi-month review of country-specific conditions and refle...
-
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis
LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's Universi...
-
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 The syringe features a next-generation ergonomic design that enhances precision and control; includes an op...
-
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a...
-
Axelera AI obtient plus de 250 millions de dollars pour la croissance commerciale internationale
EINDHOVEN, Pays-Bas--(BUSINESS WIRE)--Axelera AI, leader européen du matériel d’accélération de l’IA, a annoncé son dernier tour de financement mené par Innovation Industries, avec la participation de fonds et d’investisseurs de premier plan, dont BlackRock et SiteGround Capital en tant que nouveaux investisseurs, ainsi que des investisseurs historiques tels que Bitfury, CDP Venture Capital, European Innovation Council Fund, la Société fédérale de participations et d’investissement de Belgique...